Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 1/2 1Phase 1 1

Status

Unknown 4Completed 2

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 2Gynecologic 2Gastrointestinal 2

Conditions

Stomach Neoplasms 56Carcinoma, Hepatocellular 42Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Lung Neoplasms 9Esophageal Neoplasms 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Glioma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Recurrence × apatinib × Clear all
NCT04047017 2021-07-30

GTN

Peking Union Medical College Hospital

Phase 2 Completed
20 enrolled
Gynecologic

Recurrence, Gestational Trophoblastic Disease

NCT04476459 2021-03-15

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Sun Yat-sen University

Phase 1/2 Unknown
33 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT03913182 2020-02-05

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Shanghai Chest Hospital

Phase 2 Unknown
39 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Recurrence

NCT03376958 2019-07-25

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Zhengzhou University

Phase 4 Completed
32 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03298074 2017-09-29

Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

Guangxi Medical University

Phase 2 Unknown
60 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03026881 2017-03-07

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Recurrence, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡